Literature DB >> 28281104

Electroretinogram and visual field changes in a case of birdshot chorioretinopathy.

Hisham Elbaz1,2, Volker Besgen3, Klara Rechberger3, Walter Sekundo3, Eckart Apfelstedt-Sylla4.   

Abstract

PURPOSE: This case report explores the role of the visual field perimetry and electroretinogram (ERG) in cases of non-infectious uveitis in the assessment and monitoring of retinal function and response to treatment.
METHODS: A 59-year-old Caucasian female presenting with bilateral posterior uveitis newly diagnosed as birdshot chorioretinopathy (BSCR) presenting with bilateral decrease in visual acuity and cystoid macular edema, as well as a paracentral scotoma in the right eye. The diagnosis and follow-up of the case was done using visual field perimetry, optical coherence tomography (OCT), and ERG.
RESULTS: Baseline ERG showed a marked decrease in the amplitudes of the scotopic and photopic responses and a delay of peak times mainly in the right eye. Mycophenolate mofetil at 2 g/day and oral prednisolone at 1 g/kg/day were administered with gradual tapering of the corticosteroids. After 5 months, there was a noticeable improvement in the visual acuity, macular edema in OCT, and an obvious increase in the amplitudes of the ERG associated with a decrease in peak times, particularly in the 30 Hz photopic 3.0 Flicker of the right eye.
CONCLUSION: This case report highlights the importance of the peak time and wave amplitudes of the 30 Hz photopic DA 3.0 Flicker as being a sensitive parameter in the diagnosis and follow-up of BSCR.

Entities:  

Keywords:  Birdshot chorioretinopathy; Electroretinogram; Uveitis; Visual field

Mesh:

Year:  2017        PMID: 28281104     DOI: 10.1007/s10633-017-9581-2

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  8 in total

Review 1.  Diagnostic testing and disease monitoring in birdshot chorioretinopathy.

Authors:  Jason Comander; John Loewenstein; Lucia Sobrin
Journal:  Semin Ophthalmol       Date:  2011 Jul-Sep       Impact factor: 1.975

2.  Electrophysiological characterisation and monitoring in the management of birdshot chorioretinopathy.

Authors:  G E Holder; A G Robson; C Pavesio; E M Graham
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

3.  ISCEV Standard for full-field clinical electroretinography (2015 update).

Authors:  Daphne L McCulloch; Michael F Marmor; Mitchell G Brigell; Ruth Hamilton; Graham E Holder; Radouil Tzekov; Michael Bach
Journal:  Doc Ophthalmol       Date:  2014-12-14       Impact factor: 2.379

4.  Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy.

Authors:  Szilard Kiss; Muna Ahmed; Erik Letko; C Stephen Foster
Journal:  Ophthalmology       Date:  2005-06       Impact factor: 12.079

5.  Birdshot retinochoroiditis: long term follow-up of a chronically progressive disease.

Authors:  Kean T Oh; Nancy J Christmas; James C Folk
Journal:  Am J Ophthalmol       Date:  2002-05       Impact factor: 5.258

6.  Standardized visual field assessment for patients with birdshot chorioretinopathy.

Authors:  Lynn K Gordon; Raquel Goldhardt; Gary N Holland; Fei Yu; Ralph D Levinson
Journal:  Ocul Immunol Inflamm       Date:  2006-12       Impact factor: 3.070

7.  Electroretinographic monitoring in birdshot chorioretinopathy.

Authors:  Lucia Sobrin; Byron L Lam; Mu Liu; William J Feuer; Janet L Davis
Journal:  Am J Ophthalmol       Date:  2005-07       Impact factor: 5.258

8.  HLA-A29-positive Birdshot Chorioretinopathy in a Hispanic Patient.

Authors:  Dina Baddar; Debra A Goldstein
Journal:  Ocul Immunol Inflamm       Date:  2014-07-10       Impact factor: 3.070

  8 in total
  1 in total

1.  Electroretinogram abnormalities in non-infectious uveitis often persist.

Authors:  Anna H Brouwer; Gerard C de Wit; Ninette H Ten Dam; Ralph Wijnhoven; Maria M van Genderen; Joke H de Boer
Journal:  Acta Ophthalmol       Date:  2020-03-19       Impact factor: 3.761

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.